Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + G-CSF for Stem Cell Mobilization in MM and NHL
NCT02037256Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jul 2011
- Primary completion
- Jan 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of bortezomib in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), sponsored by Barbara Ann Karmanos Cancer Institute. Started Jul 2011; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02037256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02037256.